From ebe0990f5ef12f07adc39230cadad19e3084d9f6 Mon Sep 17 00:00:00 2001
From: Isabell Alexandra Guckes <isabell.guckes@uni-bielefeld.de>
Date: Wed, 25 Sep 2024 19:00:21 +0000
Subject: [PATCH] Update file drug-data.tsx
---
src/data/drug-data.tsx | 2 +-
1 file changed, 1 insertion(+), 1 deletion(-)
diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 4a634f01..ac91d214 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -37,7 +37,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
examples: [
{
title: "Trikafta", //quelle 4
- text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation = 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
+ text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation = 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
},
{
title: "Symdeko", //quelle 1
--
GitLab